|
|
Article: Icagen Reports Fourth Quarter and Full Year 2004 Financial Results and Reports Results of Phase Ib Clinical Trial of ICA-69673.
- Article from:
- PR Newswire
- Article date:
- March 30, 2005
CopyrightCOPYRIGHT 2005 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
RESEARCH TRIANGLE PARK, N.C., March 30 /PRNewswire-FirstCall/ -- Icagen, Inc. reported today its financial results for the fourth quarter and year ended December 31, 2004. For the fourth quarter of 2004, the Company reported revenues of $2.9 million and a net loss of $4.5 million. For the year ended December 31, 2004, the Company reported revenues of $6.5 million and a net loss of $16.7 million.
Richard Katz, M.D., Chief Financial Officer of Icagen, noted, "2004 was a year of significant achievements for Icagen. In addition to the completion of our Phase II study of ICA-17043 and the formation of our collaboration with McNeil, we continued to make progress ...